Literature DB >> 28966446

Evaluation of medication compliance for secondary prevention of acute coronary syndrome.

Dalvir Gill1, Elizabeth A Feldman1, Kan Liu1.   

Abstract

To prevent recurrence of acute coronary syndrome (ACS), national practice guidelines recommend use of five-drug combination therapy. Our study assessed the proportion of patients discharged on all five medications following ACS and determined reasons for nonadherence. A retrospective, single-center chart review was conducted at a tertiary academic medical center. Patients 18 years and older who were admitted to the cardiac care unit with a diagnosis of ACS between January 2013 and January 2015 were included. Overall, 200 patients were screened and 155 were included in the study. Half of the patients received all guideline-recommended classes of pharmacological agents at discharge. The other half-78 patients-did not receive the five-drug combination, of whom 48 (62%) had reasons documented for nonadherence. Our study's findings suggest that rates of adherence need to improve given the clear benefits of these medications.

Entities:  

Year:  2017        PMID: 28966446      PMCID: PMC5595376          DOI: 10.1080/08998280.2017.11930208

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  12 in total

Review 1.  Leveraging observational registries to inform comparative effectiveness research.

Authors:  Bimal R Shah; Joseph Drozda; Eric D Peterson
Journal:  Am Heart J       Date:  2010-07       Impact factor: 4.749

2.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrøm; Niels Gadsbøll; Pernille Buch; Jens Friberg; Søren Rasmussen; Lars Køber; Steen Stender; Mette Madsen; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2006-01-06       Impact factor: 29.983

Review 3.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

4.  Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry.

Authors:  Nicolas Danchin; Jean-Pierre Cambou; Guy Hanania; Zena Kadri; Nathalie Genès; Jean-Marc Lablanche; Didier Blanchard; Laurent Vaur; Pierre Clerson; Pascal Guéret
Journal:  Am Heart J       Date:  2005-12       Impact factor: 4.749

5.  Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.

Authors:  Connie Newman; John Tsai; Michael Szarek; Don Luo; Eric Gibson
Journal:  Am J Cardiol       Date:  2005-11-15       Impact factor: 2.778

Review 6.  Update: Acute coronary syndromes (IX). Secondary prevention strategies for acute coronary syndrome.

Authors:  Juan Quiles; Beatriz Miralles-Vicedo
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2014-07-23

7.  beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.

Authors:  Jeffrey J Goldberger; Robert O Bonow; Michael Cuffe; Alan Dyer; Yves Rosenberg; Robert O'Rourke; Prediman K Shah; Sidney C Smith
Journal:  Am Heart J       Date:  2010-09       Impact factor: 4.749

Review 8.  Statin safety: an overview and assessment of the data--2005.

Authors:  Harold Bays
Journal:  Am J Cardiol       Date:  2006-02-08       Impact factor: 2.778

9.  Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.

Authors:  Helen Y Lee; Catherine E Cooke; Teisha A Robertson
Journal:  J Manag Care Pharm       Date:  2008-04

10.  Present and future of secondary prevention after an acute coronary syndrome.

Authors:  Pierre-Frederic Keller; Sebastian Carballo; David Carballo
Journal:  EPMA J       Date:  2011-10-25       Impact factor: 6.543

View more
  1 in total

1.  Pharmacist role to enhance the prescribing of hospital discharge medications for patients after heart attack.

Authors:  Amina M Jabri; Hayder Ch Assad; Ali Azeez Al-Jumaili
Journal:  Saudi Pharm J       Date:  2020-02-17       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.